This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SomaLogic common stock and public warrants have ceased trading and will no longer be listed on the NASDAQ Global Select Market. The combined company is moving forward focused on: Expanding its commercial reach and maximizing cross-selling opportunities through complementary offerings and end markets.
Based on current expected terms and conditions of the new non-recourse financing, the acquisition is expected to provide incremental annual levered asset CAFD on a five-year average basis of approximately $9 million beginning January 1, 2026. Clearway continues its successful track record of executing accretive, third-party acquisitions.
We urge you to vote "FOR" the Merger on SomaLogic's proxy card for three key reasons: 1. The Merger delivers compelling long-term upside, positions SomaLogic for leadership in the current market and reduces risk. We expect this will deliver $300 million in combined revenue by 2026. To be clear, this transaction is not a sale.
Strategic and Financial Benefits Creates a multi-omic technology leader, targeting large, high growth markets with a diverse portfolio of life science tools that power industry-leading throughput and data quality. Expands commercial reach and maximizes cross-selling opportunities through complementary offerings and end markets.
Executive Summary As we enter 2025, business owners in the Lower Middle Market face unprecedented market conditions alongside critical tax policy changes. Key Takeaways: M&A conditions favor sellers, with record private equity capital, active strategic buyers, and favorable interest rates following recent Fed cuts to 4.25-4.50%
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content